Abgenix trial could spell trouble for ImClone

Abgenix's big success in the latest clinical trials for cancer drug, Panitumumab, could mean problems for its competitor, Erbitux by ImClone. Panitumumab appears to have an advantage over Erbitux. See previous biotech post for more on Abgenix trial.

More biotech